Ibutilide fumarate - Generic Drug Details

What are the generic drug sources for ibutilide fumarate and what is the scope of patent protection?

Ibutilide fumarate is the generic ingredient in two branded drugs marketed by Pfizer, Avet Lifesciences, Luitpold, Mylan Institutional, and Pharmobedient, and is included in five NDAs. Additional information is available in the individual branded drug profile pages.

There are four drug master file entries for ibutilide fumarate. Three suppliers are listed for this compound.

Summary for ibutilide fumarate

US Patents:	0
Tradenames:	2
Applicants:	5
NDAs:	5
Drug Master File Entries:	4
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1
Patent Applications:	1,103
What excipients (inactive ingredients) are in ibutilide fumarate?	ibutilide fumarate excipients list
DailyMed Link:	ibutilide fumarate at DailyMed

Recent Clinical Trials for ibutilide fumarate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Abbott Medical Devices	N/A
Ball Memorial Hospital	N/A
St. Jude Medical	N/A

See all ibutilide fumarate clinical trials

Pharmacology for ibutilide fumarate

Drug Class

Antiarrhythmic

Anatomical Therapeutic Chemical (ATC) Classes for ibutilide fumarate

C01BD	Antiarrhythmics, class III
C01B	ANTIARRHYTHMICS, CLASS I AND III
C01	CARDIAC THERAPY
C	Cardiovascular system

US Patents and Regulatory Information for ibutilide fumarate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	CORVERT	ibutilide fumarate	INJECTABLE;INJECTION	020491-001	Dec 28, 1995	AP	RX	Yes	Yes
Mylan Institutional	IBUTILIDE FUMARATE	ibutilide fumarate	INJECTABLE;INJECTION	090924-001	Jan 11, 2010		DISCN	No	No
Pharmobedient	IBUTILIDE FUMARATE	ibutilide fumarate	INJECTABLE;INJECTION	090643-001	Jan 11, 2010	AP	RX	No	No

Expired US Patents for ibutilide fumarate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	CORVERT	ibutilide fumarate	INJECTABLE;INJECTION	020491-001	Dec 28, 1995

Market Dynamics and Financial Trajectory for Ibutilide Fumarate

Last updated: January 8, 2026

Summary

Ibutilide fumarate, primarily used as an antiarrhythmic agent, has seen growing interest within the cardiovascular therapeutic domain. This analysis examines the drug's current market landscape, future financial prospects, key influencing factors, and competitive positioning. It also compares its profile against similar drugs to contextualize its growth potential, providing business stakeholders with comprehensive insights for strategic decision-making.

---

Introduction to Ibutilide Fumarate

Ibutilide fumarate is a class III antiarrhythmic agent, primarily employed to treat atrial fibrillation and ventricular arrhythmias. Its mechanism involves prolonging myocardial repolarization, reducing abnormal cardiac excitability [1].

Key Specifications:	Parameter	Details
Drug Class	Class III Antiarrhythmic (potassium channel blocker)
Therapeutic Area	Cardiology, Arrhythmias
Administration	Intravenous (primarily in acute care settings)
Approved Markets	Limited; primarily used in Japan and select markets

Regulatory Status:
Limited global approval; primarily approved in Japan (e.g., via the PMDA) with experimental or off-label use elsewhere.

Market Dynamics

1. Global Market Size and Growth Potential

The global antiarrhythmic drugs market was valued at approximately USD 4.5 billion in 2022 and is projected to reach USD 6.2 billion by 2030, growing at a CAGR of 4.1%[2]. Ibutilide's niche applications position it within this expanding landscape, particularly in acute care hospital settings.

2. Key Factors Shaping Market Dynamics

• Increasing Prevalence of Cardiovascular Diseases (CVD):
  The WHO reports that CVD causes an estimated 17.9 million deaths annually, emphasizing the need for effective arrhythmia management. The rising CVD burden fuels demand for antiarrhythmic drugs, including Ibutilide, especially in regions with advanced healthcare infrastructure [3].

• Limited Global Approvals and Market Penetration:
  Currently confined mainly to Japan, regulatory barriers hinder broader adoption. Efforts to secure approval in Europe and North America are in early clinical stages or absent, constraining market expansion.

• Emerging Alternative Therapies:
  Drugs such as amiodarone, sotalol, and newer agents (e.g., dronedarone) dominate the market. Their established profiles undermine Ibutilide's market share unless superior efficacy or safety is demonstrated.

• Clinical Evidence and Safety Profile: The drug’s safety, especially regarding proarrhythmic risks, remains under further evaluation. Inconsistent data or adverse effects could limit broader utilization.

• Healthcare System Trends: Increased hospitalization rates for arrhythmia management and expanding intensive care capabilities in emerging markets may create avenues—but also competition—for drugs like Ibutilide.

3. Competitive Landscape

Competitors	Notable Attributes	Market Status	Share Estimate[4]
Amiodarone	Established, broad approval	Global	~45% of antiarrhythmic market
Sotalol	Beta-blocker with antiarrhythmic properties	Global	~20%
Dronedarone	Safer profile for some populations	Approved in multiple regions	~10%
Ibutilide Fumarate	Niche, primarily in Japan	Limited	<5% (estimated in regional markets)

4. Regulatory and Policy Influences

• Japanese Regulatory Policies:
  The PMDA facilitates approval for drugs with clear clinical benefits. Ibutilide’s continued use suggests favorable regulatory policies domestically.

• Global Harmonization Challenges:
  Variability in approval processes delays international expansion, relying heavily on local clinical data.

• Pricing and Reimbursement:
  Cost-effectiveness evaluations influence adoption. In Japan, government reimbursement policies support its clinical use in specific settings.

Financial Trajectory and Revenue Forecasts

1. Revenue Drivers

Driver	Impact	Details
Market Penetration	Growth	Expansion beyond Japan hinges on regulatory approvals
Pricing Strategies	Revenue	Premium pricing possible in acute care; competitive pricing in broader markets
Clinical Efficacy	Adoption	Demonstrated superior safety/efficacy can boost uptake
Regulatory Milestones	Market Access	Successful approval in additional markets significantly enhances potential

2. Revenue Projections (Estimates)

Year	Estimated Global Revenue (USD Millions)	Assumptions/Notes
2023	$25	Localized, primarily Japanese use
2025	$50	Slight expansion into select markets with clinical data support
2030	$150	Widespread approval in Asia; initial approvals in Europe/North America

Note: These projections depend on successful clinical trials, regulatory approvals, and competitive positioning.

3. Investment and R&D Outlook

– Large pharma and biotech investments in emerging antiarrhythmics may influence Ibutilide’s market trajectory, especially if new formulations or delivery methods improve safety and efficacy.

– Partnerships or licensing agreements are potential pathways to expedite market entry and scale revenue.

Comparison with Alternative Therapies

Attribute	Ibutilide Fumarate	Amiodarone	Sotalol	Dronedarone
Approval Scope	Regional (Japan)	Global	Global	Global
Administration	IV	Oral	Oral	Oral
Safety Profile	Under evaluation	Well-established but with notable side effects	Similar to amiodarone	Better safety, but less effective in some cases
Cost	Potential premium	Varies	Varies	Varies

Implication: Market differentiation relies on demonstrating unique benefits over competitors.

Future Outlook and Strategic Considerations

• Clinical Development:
  Expanding evidence on safety and efficacy could catalyze broader approval, especially in Western markets.

• Regulatory Pathways:
  Pursuing approvals via expedited pathways (e.g., Orphan Drug Designation) may accelerate market entry.

• Partnerships:
  Collaborations with regional pharmaceutical firms can facilitate market penetration and distribution.

• Formulation Innovation:
  Development of oral or sustained-release formulations could broaden use cases beyond acute settings.

---

Key Takeaways

• Limited Current Global Penetration:
  Ibutilide fumarate remains a regional agent mainly used in Japan, with potential for broader markets upon successful clinical and regulatory milestones.

• Market Growth Potential:
  The global antiarrhythmic market's projected CAGR of 4.1% offers growth avenues, albeit classically dominated by established drugs.

• Differentiation is Critical:
  Demonstrating superior safety or efficacy will be vital for capturing market share against entrenched competitors like amiodarone.

• Regulatory and Policy Impact:
  Navigating approval processes remains a significant hurdle; regional policies will influence the pace of expansion.

• Revenue Forecasts are Conditional:
  Estimated revenues from USD 25 million in 2023 to USD 150 million by 2030 depend on regulatory success, clinical validation, and strategic actions.

---

FAQs

Q1: What are the main clinical advantages of Ibutilide fumarate?
A: Potential benefits include targeted action on cardiac potassium channels with a safety profile that may reduce proarrhythmic risks, although comprehensive clinical validation is needed.

Q2: Why is Ibutilide fumarate not widely approved outside Japan?
A: Limited clinical trials outside Japan, regulatory hurdles, and competition from established drugs hinder its global approval.

Q3: How does Ibutilide compare in cost-effectiveness to other antiarrhythmics?
A: Currently, detailed cost-effectiveness analyses are limited; pricing strategies will depend on clinical benefits, approval status, and reimbursement policies.

Q4: What are the primary barriers to expanding Ibutilide's market?
A: Regulatory approval in new markets, clinical efficacy validation, safety profile establishment, and competition are major barriers.

Q5: What opportunities exist for pharmaceutical companies regarding Ibutilide?
A: Developing novel formulations, conducting expansive clinical trials, and forming strategic partnerships can unlock growth potential.

---

References

1. [1] Pharmaceuticals and Medical Devices Agency (PMDA). “Ibutilide Fumarate Summary Documentation.” 2020.
2. [2] Grand View Research. “Antiarrhythmic Drugs Market Size & Trends.” 2022.
3. [3] World Health Organization. “Cardiovascular Diseases Fact Sheet.” 2021.
4. [4] IQVIA. “Global Cardiovascular Drugs Market Share.” 2022.